Incannex Healthcare Limited (IXHL) Stock Price & Analysis
Incannex Healthcare Limited (IXHL) — MoonshotScore 44/100 (Weak band), calculated Oct 4, 2026. Price $3.21 (-1.23%), as of the Oct 2, 2026 trading session; market cap $38.4M.
Educational signal · not a buy or sell recommendation · How to read this
Incannex Healthcare Limited · IXHL · NASDAQ
Incannex Healthcare Limited is an Australian pharmaceutical company focused on developing medicinal cannabinoid products. Their pipeline includes treatments for sleep apnea, traumatic brain injury, and inflammatory lung conditions.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Incannex Healthcare (IXHL)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Cheap, but stalling growth, average quality and a middling balance sheet. Business Quality: Average; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $66,616 (Q4 FY2025, quarter ended Jun 30, 2025)
- EPS beat 4 of 8
- Altman Z 0.65 · Piotroski F 3
Holding back: soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 43 | Weak | |
| 43 | Weak |
The score was 44 in the stored Oct 3, 2026 snapshot and remains 44 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Business Quality +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.21 | |
| Change on the day | -1.23% | |
| 52-week range | $2.49 – $14.94 | |
| Market capitalisation | $38.4M | |
| Price / earnings (trailing) | -0.22 | |
| Shares traded on the day | 51.8K |
Price & events
Other perspectives
Council score for Incannex Healthcare (IXHL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the IXHL film — every key number, told as a short cinematic story
~2 min · open the film
What is Incannex Healthcare (IXHL), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Incannex Healthcare Limited (IXHL) is listed on NASDAQ. It employs 12 people and is led by Joel Bradley Latham. In Q4 FY2025 it reported revenue of $66,616 and net income of -$36M. The market values it at $38.4M.
What do the latest results show for Incannex Healthcare (IXHL)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $66,616. Against analyst estimates the company has EPS beat 4 of 8 reports.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $66,616 | -$36M | -$0.69 (diluted) |
| Q2 FY2025 | $108,987.2 | -$8M | -$0.87 (diluted) |
What are the financial strengths and risks for Incannex Healthcare (IXHL)?
Short answer
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is soft growth, weak price trend. The distress and quality screens read Altman Z 0.65 · Piotroski F 3. Trailing ratios: ROA -62.2% · current ratio 41.56 · earnings yield -108.5% · free-cash-flow yield -30.0%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.65 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Incannex Healthcare (IXHL)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $700,000 · EPS -1.57 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q4 FY2025) was filed Sep 29, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How is Incannex Healthcare scored?
Short answer · as of
A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.
| Company | Price | Market value | Score |
|---|---|---|---|
| $9.75 Oct 2, 2026 | $88.2M | — Model unavailable | |
| $17.08 Oct 2, 2026 | $90.6M | — Model unavailable | |
| $9.96 Oct 2, 2026 | $119M | — Model unavailable | |
| $4.49 Oct 2, 2026 | $184M | — Model unavailable | |
| $5.71 Oct 2, 2026 | $206M | — Model unavailable | |
| $2.79 Oct 2, 2026 | $222M | — Model unavailable | |
| $8.23 Oct 2, 2026 | $245M | — Model unavailable | |
| $7.19 Oct 2, 2026 | $564M | — Model unavailable | |
| $9.99 Oct 2, 2026 | $591M | — Model unavailable | |
| $10.94 Oct 2, 2026 | $626M | — Model unavailable | |
| $4.59 Oct 2, 2026 | $669M | — Model unavailable | |
| $9.75 Oct 2, 2026 | $690M | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $700,000
- EPS estimate
- $-1.57
Measured against a quoted price of $3.21 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Incannex Healthcare (IXHL)?
- Incannex Healthcare Announces First Patient Dosed In Phase 2 DReAMzz Dose-Optimization Study Of IHL-42X In Obstructive Sleep Apnea Across 14 U.S. Sites
- Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
- Incannex Healthcare Receives Final A$5.1M R&D Tax Incentive Refund Following Approval Of Its Overseas Findings And Amendment Of Its FY25 Tax Return
- Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
Incannex Healthcare Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the IXHL research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for IXHL?
IXHL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Incannex Healthcare Limited is an Australian pharmaceutical company focused on developing medicinal cannabinoid products.
Is IXHL a good stock to buy?
Stock Expert AI does not rate IXHL buy, sell or hold. Incannex Healthcare Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IXHL stock price today?
The last price recorded on this page for Incannex Healthcare Limited (IXHL) is $3.21, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for IXHL?
The main risks for Incannex Healthcare Limited include the uncertainty of clinical trial outcomes, potential delays in regulatory approvals, and competition from established pharmaceutical companies.
What are the key factors to evaluate for IXHL?
Incannex Healthcare Limited (IXHL) holds a MoonshotScore in the low range. Analysts target $18.22 (+468%). Focus on cannabinoid-based therapies positions the company in a high-growth, albeit risky, segment of the pharmaceutical market. Not financial advice.
How frequently does IXHL data refresh on this page?
IXHL's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IXHL's recent stock price performance?
Incannex Healthcare Limited (IXHL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cannabinoid-based therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IXHL overvalued or undervalued right now?
Incannex Healthcare Limited (IXHL) is loss-making, so its trailing P/E is negative (-0.22x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $18.22 (+468%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of IXHL?
Fractional-share availability for Incannex Healthcare Limited (IXHL) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (21 figures)
The 21 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 10 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $3.21 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T12:24:45.044Z. | |
px.change | Change on the day | -1.23% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $38.4M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T12:24:44.061Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.04 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2025 | $66,616 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -0.22 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 51.8K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q4 FY2025 | -$36M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 2 quarters through Q4 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 12 transactions · 0 purchases, 0 sales, 12 other transactions · 7 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z 0.65 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
px.range52 | 52-week range | $2.49 – $14.94 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.employees | Employees | 12 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.ceo | Chief executive | Joel Bradley Latham | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -62.2% · current ratio 41.56 · earnings yield -108.5% · free-cash-flow yield -30.0% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $700,000 · EPS -1.57 · 1 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-02 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $700,000 | UNRECORDED | Stored analyst estimates — Captured 2026-10-02 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-1.57 | UNRECORDED | Stored analyst estimates — Captured 2026-10-02 · Expired observation |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 44 of 100 · Weak · pillars 45 / 46 / 84 / 7 / 32 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 44 (stored snapshot Oct 3, 2026) → 44 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.